RCKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rocket Pharmaceuticals Inc (RCKT) is not a strong buy for a beginner, long-term investor at this moment. The company's financial performance is weak, with declining net income and EPS. Despite positive analyst sentiment and recent FDA approval for Kresladi, the stock is currently in a pre-market downtrend, and technical indicators do not show a strong entry point. Additionally, there are no Intellectia Proprietary Trading Signals for this stock today, and options data indicates low trading sentiment. While the long-term potential of the company may be promising, this is not an optimal entry point for the investor's profile.
The MACD histogram is negative (-0.0906) and contracting, suggesting a bearish trend. RSI is at 38.252, indicating no clear signal. Moving averages are converging, and the stock is trading near its support level (S1: 3.369). The pre-market price is down 2.22%, indicating short-term weakness.
FDA approval of Kresladi for pediatric leukocyte adhesion deficiency-I, along with a rare pediatric disease priority review voucher that could provide $100M-$200M in non-dilutive capital. Analysts have raised price targets and reiterated positive ratings, citing strong management execution and potential for the cardiac gene-therapy pipeline.
Weak financial performance in Q4 2025, with a significant drop in net income (-29.49%) and EPS (-38.71%). The lack of pricing commentary and timeline details around Kresladi may have disappointed investors, contributing to the recent negative price reaction.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped significantly to -$42.54M, and EPS fell to -0.38. Gross margin remained at 0 with no improvement.
Analysts are generally positive, with multiple firms raising price targets (ranging from $9 to $16) and reiterating Buy or Outperform ratings. However, Goldman Sachs maintains a Sell rating with a $3 price target.
